135326-11-3|Gadoxetic acid|Gadoxetic acid|-范德生物科技公司

Gadoxetic acid

NMR下载 COA and HPLC MSDS下载
names：
Gadoxetic acid
CAS号：
135326-11-3
MDL Number：
MF(分子式)： C23H30GdN3O11 MW(分子量)： 681.75
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
DBK501851-500mg	500mg		¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00
DBK501851-100mg	100mg		¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Gadoxetic acid
英文别名	Gadoxetic acid
CAS号	135326-11-3
SMILES	[Gd+3].[H][C@@](CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)(CC1=CC=C(OCC)C=C1)N(CC(O)=O)CC(O)=O
Inchi
InchiKey
分子式 Formula	C23H30GdN3O11
分子量 Molecular Weight	681.75
闪点 FP	NA
熔点 Melting point	NA
沸点 Boiling point	NA
Polarizability极化度	2
密度 Density	NA
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid
储藏条件 Storage conditions

Gadoxetic acid使用注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。
5.取药品时尽量采用多个药勺分别使用，使用后清洗干净。
6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。
大规格定制：定制产品请将信息发送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

产品说明	Atosiban is a synthetic peptide oxytocin antagonist5,1. It resembles oxytocin with has modifications at the 1, 2, 4, and 8 positions. The N-terminus of the cysteine residue is deaminated to form 3-mercaptopropanic acid at position 1, at position 2 L-tyrosine is modified to D-tyrosine with an ethoxy group replacing the phenol , threonine replaces glutamine at postion 4, and ornithine replaces leucine at position 8.It binds to membrane bound oxytocin receptors on the myometrium and prevents oxytocin-stimulated increases in inositol triphosphate production1. This ultimately prevents release of stored calcium from the sarcoplasmic reticulum and subsequent opening of voltage gated calcium channels. This shutdown of cytosolic calcium increase prevents contractions of the uterine muscle, reducing the frequency of contractions and inducing uterine quiescence.Atosiban has more recently been found to act as a biased ligand at oxytocin receptors3,4. It acts as an antagonist of Gq coupling, explaining the inhibition of the inositol triphosphate pathway thought to be responsible for the effect on uterine contraction, but acts as an agonist of Gi coupling. This agonism produces a pro-inflammatory effect in the human amnion, activating pro-inflammatory signal tranducer NF-κB4. It is thought that this reduces atosiban's effectiveness compared to agents which do not produce inflammation as inflammatory mediators are known to play a role in the induction of labour.TargetActionsOrganismAOxytocin receptorantagonistHumansUVasopressin V1a receptorantagonistHumansUVasopressin V1b receptorantagonistHumansUVasopressin V2 receptorantagonistHumans
Introduction	Not Available
Application1
Application2	Antagonist
Application3